- Language: English
- 306 Pages
- Published: August 2013
- Region: Global
Stem Cell Research Products: Opportunities, Tools & Technologies
- Published: December 2012
- Region: Global
- 118 Pages
Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into any mature cell type. Several broad categories of stem cells exist, including embryonic stem cells, derived from blastocysts; fetal stem cells, obtained from aborted fetuses; adult stem cells, found in adult tissues; cord blood stem cells, isolated from umbilical tissue; dental stem cells, derived from deciduous teeth; cancer stem cells, which give rise to clonal populations of cells that form tumors or disperse in the body; and animal stem cells, derived from non-human sources.
In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult organisms, stem and progenitor cells act as a repair system for the body, replenishing specialized cells. Of interest to researchers is the potential for use of stem cells in regenerative medicine to treat conditions ranging from diabetes, to cardiovascular disease and neurological disorders. Additionally, the ability to use stem cells to improve drug target validation and toxicology screening is of intense interest to pharmaceutical companies. Stem cells are also being studied for their ability to improve both the understanding and treatment of birth disorders.
To facilitate research resulting from interest in these far-ranging applications, a large and growing stem cells research products market has emerged. Large companies selling stem cell research products include Life Technologies, BD Biosciences, Thermo Fisher Scientific, and Millipore, although dozens of other suppliers exist as well. Products offered by these companies include: antibodies to stem cell antigens, bead-based stem cell separation systems, stem cell protein purification and analysis tools, tools for DNA and RNA-based characterization of stem cells, stem cell culture and media reagents, stem cell specific growth factors and cytokines, tools for stem cell gene regulation, a range of stem cell services, tools for in vivo and in vitro stem cell tracking, and stem cell lines.
Currently, the federal government is an important, although not dominant, source of funding for stem cell research. The reason is that states are spending almost as much as the federal government on stem cell research and are actually spending more than the federal government on human embryonic stem cell (hESC) research. Private sources also contribute a huge about of funding, with analysis of recent large gifts summing to over $1.7 billion.
Furthermore, growth in research into stem cells has exploded in the past decade. And so the market to supply stem cell research products has grown to meet this huge demand.
- There are now over one million stem cell researchers in 283 countries worldwide.
- There were 17 companies when we first started monitoring the stem cell research products market in 2006. This has risen to 90 companies today, a 5.3-fold increase.
- The stem cell research products market (excluding stem cell antibodies) was valued at $1.28 billion for the full year 2011 and is projected to increase to $2.10 billion by 2016.
- The total market for all types of stem cell products – including stem cell research products, stem cell antibodies, and stem cell therapies - was valued at $5.72 billion for the full year 2011.
The report identifies, defines, and quantifies each market segment within the stem cell product industry, including Stem Cell Research Products, Stem Cell Antibodies, and Stem Cell Therapies.
Because of the massive size of this market, developing either niche products or a diverse stem cell product line represents a significant opportunity for research supply companies. This report explores current market conditions and provides guidance for companies interested in developing strategically positioned stem cell product lines.
With recent advances in induced pluripotent stem cells (iPSC) creating excitement in stem cell research circles and U.S. President Obama expanding the number of human embryonic stem cell lines (hESC) available for federally funded research, rapid changes have been occurring in the field of stem cell science. Not surprisingly, analysis of stem cell publication rates, grant activity, patent applications, and new product launches reveal that stem cell research products have now become the single most valuable product opportunity available to life science suppliers.
The market report "Stem Cell Research Products: Opportunities, Tools & Technologies" was produced using a detailed end-user survey of research scientists, in which over 400 stem cell researchers from the U.S., Canada, Europe, Asia, Australia and other international regions participated. The findings represent perspectives across a global audience of researchers.
As a technology company, BioInformant also used proprietary data-derivation techniques to quantify and assess critical trends in the stem cells marketplace. The result is a high value, full-content report designed to inform the decision-making of research supply companies.
Featured elements of this report include:
- What are novel stem cells research products that can be developed?
- What stem cells types are most frequently used by research scientists?
- Which species of stem cells do scientists prefer and what are the factors driving this preference (access, pricing, funding, handling advantages)?
- What are the most frequently used stem cell markers?
- What are the most common research applications, and how do they differ by segment (academic, industrial, and government)?
- Who are the leading suppliers of stem cell products?
- What stem cell product categories are already available in the marketplace?
- What are current grant, patent, and scientific publication rate trends?
- What are the major funding sources, trends, and dollar values, for domestic and international researchers?
- What is the size of the stem cell research products marketplace and how fast is it growing?
- What are communication strategies for accessing the marketplace?
- And much more...
In summary, the report provides detailed insight into the stem cells research products marketplace and the needs of active stem cell scientists.
- Cellartis AB
- Buck Institute
- BD Biosciences
Top Research Institutions Performing Stem Cell Research
- University of Wisconsin, including WARF, WiCell, and the WISC Bank
- Johns Hopkins University
- US National Institutes of Health (NIH)
- California Institute for Regenerative Medicine SHOW LESS READ MORE >
II. BACKGROUND: TYPES OF STEM CELLS
A. Human Embryonic Stem Cells (hESCs)
1. Early, 5-7 days (totipotent)
2. Gonadal Ridge, 6 months (multipotent)
B. Fetal Stem Cells (pluripotent)
C. Umbilical Cord Stem Cells (multipotent)
1. Cord Blood
2. Cord Matrix (“Wharton's Jelly”)
D. Dental Stem Cells (multipotent)
E. Adult Stem Cells (multipotent)
1. Hematopoietic Stem Cells
2. Mesenchymal Stem Cells
3. Neural Stem Cells
F. Cancer Stem Cells (multipotent)
G. Induced Pluripotent Stem Cells (iPSCs)
H. Novel (recently discovered and uncharacterized) Stem Cell Types
1. Neural Rosette Cells (R-NSCs)
2. Very Small Embryonic Like (VSEL) Stem Cells
III. STEM CELL RESEARCH APPLICATIONS
A. Regenerative Medicine (Cell-Based Therapies)
1. Diabetes Mellitus
2. Cardiovascular Disease
3. Neurological Disease
4. Autoimmune Disease
5. Hematopoietic Disease and Transplantation Research
6. Orthopedic Repair
7. Cancer Research
8. Birth Defect Research
B. Non Cell-Based Applications
1. Assays to Aid Early Stage Discovery
2. Improved Prediction of Human Responses
3. Drug Development with Humanized Mouse Models
4. Genetically-Engineered Stem Cell Lines for Screening
5. Pluripotent Stem Cell Lines for Target Validation and Drug Screening
C. Birth Defect Research
IV. KEY MARKET COMPETITORS: PROVIDERS OF DIVERSE STEM CELL PRODUCT LINES
A. Invitrogen, a brand of Life Technologies (previously Invitrogen Corporation)
1. Stem Cell Products
a. Isolation and Characterization Products
b. Expansion and Differentiation Products
a. Invitrogen and Cellartis AB
b. Invitrogen and Novocell
c. Invitrogen and the Buck Institute
B. BD Biosciences
1. Stem Cell Products
2. Collaborations: BD Biosciences and Stem Cell Technologies
C. Comparison of Stem Cell Publication Rates: Invitrogen versus BD Biosciences
V. PRODUCT AREAS
A. Primary Antibodies
B. Bead-based Cell Separations Systems
C. Fluorescent-based Labeling and Detection
D. Protein Purification and Analysis Tools
1. Protein Purification
2. Stem Cell Protein Analysis
3. Quantitative Proteomics
E. DNA/RNA Based Characterization
1. Tools for DNA- and RNA-based Characterization
2. Stem Cell HLA Typing
3. Stem Cell Nucleic Acid Extraction and Purification, PCR/qRT-PCR Reagents
F. Isolation / Characterization Services
1. Stem Cell HLA Typing Services
2. Stem Cell Custom Services
3. Stem Cell Custom Antibodies
G. Stem Cell Culture Media and Reagents
H. Growth Factors and Cytokines
I. Stem Cell Gene Regulation
J. In vivo / In vitro Stem Cell Tracking
K. Expansion / Differentiation Services
1. Stem Cell Media Services
2. RNAi Services
L. Stem Cell Lines
VI. MARKET SIZE
A. Definition: Stem Cell Research Products
B. Experimental Approach
C. Stem Cell Research Products, Market Size (in Millions)
D. Stem Cell Antibodies, Market Size (in Millions)
E. Stem Cell Therapies, Market Size (in Billions)
VII. CURRENT MARKET ASSESSMENT
A. Breakdown of Research Segments by End-user Application
1. Basic Research
2. Applied Research
a. Autologous and Allogeneic Cell Therapy
b. Toxicology Screening for Drug Discovery and Development
B. Breakdown of Stem Cell Research by Cell Type
1. Cord Blood Stem Cells
2. Dental Stem Cells
C. Breakdown of Stem Cell Research by Species
D. Publication Rate Analysis
1. Overview of Stem Cell Publication Rates
2. Comparative Analysis of Stem Cell Publication Trends
E. Sources of Stem Cell Funding
F. Patent Analysis
G. Geographical Analysis: Domestic vs. International Status
VIII. MARKET TRENDS: DETAILED END-USER SURVEY (SCIENTIST PANEL)
A. Survey Overview
B. Characterization of Market Survey Respondents
1. Geographic Distribution of Respondents
2. Respondent Breakdown by Industry Affiliation
3. Breakdown of Respondents by Duration of Stem Cell Activity
C. Survey Findings
1. Breakdown of Stem Cell Research Activity by Cell Type
2. Dominant Stem Cell Markers
3. Market Penetration of Stem Cell Markers by Cell Type
a. Human Embryonic Stem Cell (hESCs)
b. Mesenchymal Stem Cell (MSCs)
c. Neural Stem Cells (NSCs)
d. Hematopoietic Stem Cells (HSCs)
D. Preferred Providers of Stem Cell Antibodies
IX. MARKET FORECASTS
A. Near-term (1-3yrs): Stem Cells as Tools for Drug Discovery
B. Short-term (3-5yrs): Therapies Involving Cord Blood and Adult Stem Cells
C. Long-Term (10yrs): Therapies involving hESCs
X. STRATEGIES FOR ACCESSING THE MARKETPLACE
A. Top Research Institutions Performing Stem Cell Research
1. University of Wisconsin, including WARF, WiCell, and the WISC Bank
2. Johns Hopkins University
3. US National Institutes of Health (NIH)
4. California Institute for Regenerative Medicine
B. Events of Interest
Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into any mature cell type. Several broad categories of stem cells exist, including:
- Embryonic stem cells, derived from blastocysts
- Post-natal stem cells, derived from newborn tissues
- Adult stem cells, found in adult tissues – including Hematopoietic stem cells, Mesenchymal stem cells, and Neural stem cells
- Induced pluripotent stem cells, reprogrammed from adult cells
- Cancer stem cells, which give rise to clonal populations of cells that form tumors or disperse in the body
- Animal stem cells, derived from non-human sources
Stem cells are still a relatively new discovery, as the first mouse embryonic stem cells were derived from embryos in 1981, but it was not until 1995 that the first successful culturing of embryonic stem cells from non-human primates occurred and not until November 1998 a technique was developed to isolate and grow embryonic stem cells from human blastocysts. In 2006, induced pluripotent stem cells were produced for the first time from mouse cells and in 2007 there were produced from human cells. Furthermore, it was not until 2008 that the first full transplant of a human organ grown from adult stem cells was performed (a section of trachea was successfully transplanted into an adult woman in Spain).
The past 10 years have also witnessed the production of piPSCs, R-NSCs, and VSELs. Together, this evidence suggests that additional types of stem cells will likely be discovered, each representing new opportunities for research product development. Clearly, laboratory research into stem cell derivation, manipulation, and application is rapidly expanding.
To facilitate research resulting from these advances, a large and diverse stem cells products market has emerged. Large companies selling stem cell research products include Life Technologies, BD Biosciences, Thermo Fisher Scientific, and EMD Millipore, as well as over one-hundred other suppliers.
As of 2012, the following product categories accounted for more than 95% of all global stem cell product sales:
- Antibodies to stem cell antigens
- Bead-based stem cell separation systems
- Stem cell protein purification and analysis tools
- Tools for DNA and RNA-based characterization of stem cells
- Stem cell culture and media
- Stem cell specific growth factors and cytokines
- Tools for stem cell gene regulation
- Stem cell services and mechanisms for in vivo and in vitro stem cell tracking
- Stem cell lines
Furthermore, to sell products into the stem cell market, it is critical to understand the research applications for which stem cells being studied. One area of study is the use of stem cells to understand and treat birth disorders. However, of greater interest to researchers is the potential for use of stem cells in regenerative medicine to treat conditions ranging from diabetes, to cardiovascular disease and neurological disorders.
For pharmaceutical companies, they have intense interest in the ability to use stem cells to improve drug target validation and toxicology screening. Furthermore, it is important for bio-pharmaceutical interested in stem cell therapy applications to understand underlying market forces, and in particular, to consider progressive areas of stem cell research as opportunistic areas for drug and therapy development. This report presents a range of topics of interest to these companies as well, including how advances in stem research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.
To summarize, the four key areas that account for more than 90% for all applied stem cell research, as of 2012, include:
- Understanding and Treatment of Birth Disorders - Natal repair
- Regenerative Medicine - Reversal of injury or disease
- Drug Target Validation and Drug Delivery - Treatment of disease
- Toxicology Screening - Drug safety and efficacy assessment
Furthermore, it is crucial for stem cell companies to understand the funding environment that supports stem cell research. Currently, the U.S. federal government is an important, although not dominant, source of funding for stem cell research. The reason is that U.S. states are spending almost as much as the federal government on stem cell research and are actually spending more than the federal government on human embryonic stem cell (hESC) research. Private sources also contribute a huge about of funding, with analysis of recent large gifts summing to over $1.7 billion.
Growth in stem cell research has exploded in the past decade. And so the market to supply stem cell research products has grown to meet this huge demand. There are now over one million stem cell researchers in 179 countries worldwide. In addition, there were only 17 stem cell product companies as of 2006 and that has expanded to more than 100 today, a 6-fold increase.
Not surprisingly, trend analysis reveals rapid increases in stem cell research activity over the past five years, specifically a scientific publication rate increase of 10.4% per year. The stem cell types with the greatest year-to-year increases in publication rates over a trailing five-year period include:
- Mesenchymal stem cells
- Neural stem cells
- Induced pluripotent stem cells
While hematopoietic and embryonic stem cells represent two of the most active areas of stem cell research, at 35.2% and 22.9% of total stem cell research respectively, publication rates for these stem cell types have declined in recent years. Because research activity by stem cell type has shown divergent trends over the past few years, for research product companies to be successful, they will need to understand underlying trends in stem cell preferences, by cell type.
This market intelligence report will advantageously position your company to offer competitive stem products to a rapidly growing, well-funded research community. Highlights of this report include:
- Charts, Timelines, Metrics, and Financials
- Rates of Stem Cell Grants, Publications, and Patents
- Market Characterization and 5-Year Projections
- Breakdown of Research Activity by Application, Species, Tissue Source
- Geographical Assessment of Market Demand
- Competitive Environment Analysis, by Product Supplier
- Recent Product Evolution and Unmet Market Needs
- Key Survey Findings from Your Prospective Clients – Stem Cell Scientists
- End-User Wants, Technical Preferences, Factors Influencing Buying Decisions
- And Much More
A key element of this report is a survey of stem cell researchers, for the U.S. and worldwide. This survey reveals critical findings that include:
- Prevalence of Stem Cell Research by Cell Type
- Stem Cell Product Preferences
- Most Commonly Utilized Stem Cell Markers, by Stem Cell Type
- Most Commonly Utilized Stem Cell Antibodies, by Stem Cell Type
- Preferred Providers of Stem Cell Antibodies
- And Much More
The market intelligence contained in this report was compiled using a broad range of sources, including:
- Stem Cell Grant Funding Databases (NIH database, DoD database)
- Stem Cell Patent Databases (USPTO)
- Stem Cell Publication Databases (PubMed, Highwire Press)
- Stem Cell Product Launch Announcements (Trade Journals, Google News)
- International Surveys (Electronically distributed end-user surveys)
- And More
In summary, there is conclusive evidence that entering the stem cell research products market is fiscally worthwhile. Full-year 2011 analysis determines the size the stem cell research products market to be $2.59 billion, and the stem cell therapies market to be $3.13 billion, for a total of $5.72 billion. In addition, both markets are growing with double-digit growth. Producing stem cell research products thus represents a massive profit opportunity for research supply companies.
Producing stem cell products can involve complicated and confusing decisions, but it doesn't have to. Claim this report to reveal the current and future needs of your customer base, so you can focus your marketing efforts on the most profitable products, in the most promising research areas and within the most lucrative domestic and international markets.
Your competitors would prefer you didn't buy this report. But when you do, you'll be gaining invaluable stem cell market insights to help you control and dominate this market.
- BD Biosciences
- Buck Institute
- Cellartis AB